Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
BACKGROUND
This double-blind, parallel-group, multicenter, phase-3 study was designed to test the noninferiority of paliperidone palmitate 3-month formulation (PP3M) to the currently marketed 1-month formulation (PP1M) in patients (age 18-70 years) with schizophrenia, previously stabilized on PP1M.


METHODS
After screening (≤3 weeks) and a 17-week, flexible-dosed, open-label phase (PP1M: day 1 [150mg eq. deltoid], day 8 [100mg eq. deltoid.], weeks 5, 9, and 13 [50, 75, 100, or 150mg eq., deltoid/gluteal]), clinically stable patients were randomized (1:1) to PP3M (fixed-dose, 175, 263, 350, or 525mg eq. deltoid/gluteal) or PP1M (fixed-dose, 50, 75, 100, or 150mg eq. deltoid/gluteal) for a 48-week double-blind phase.


RESULTS
Overall, 1016/1429 open-label patients entered the double-blind phase (PP3M: n=504; PP1M: n=512) and 842 completed it (including patients with relapse). PP3M was noninferior to PP1M: relapse rates were similar in both groups (PP3M: n=37, 8%; PP1M: n=45, 9%; difference in relapse-free rate: 1.2% [95% CI:-2.7%; 5.1%]) based on Kaplan-Meier estimates (primary efficacy). Secondary endpoint results (changes from double-blind baseline in positive and negative symptom score total and subscale scores, Clinical Global Impression-Severity, and Personal and Social Performance scores) were consistent with primary endpoint results. No clinically relevant differences were observed in pharmacokinetic exposures between PP3M and PP1M. Both groups had similar tolerability profiles; increased weight was the most common treatment-emergent adverse event (double-blind phase; 21% each). No new safety signals were detected.


CONCLUSION
Taken together, PP3M with its 3-month dosing interval is a unique option for relapse prevention in schizophrenia.
['Savitz|Adam J|AJ|', 'Xu|Haiyan|H|', 'Gopal|Srihari|S|', 'Nuamah|Isaac|I|', 'Ravenstijn|Paulien|P|', 'Janik|Adam|A|', 'Schotte|Alain|A|', 'Hough|David|D|', 'Fleischhacker|Wolfgang W|WW|']
D000293:Adolescent D000328:Adult D000368:Aged D014150:Antipsychotic Agents D003692:Delayed-Action Preparations D004305:Dose-Response Relationship, Drug D004311:Double-Blind Method D005260:Female D006801:Humans D007273:Injections, Intramuscular D008297:Male D008875:Middle Aged D000068882:Paliperidone Palmitate D012559:Schizophrenia D055502:Secondary Prevention D013997:Time Factors D016896:Treatment Outcome D055815:Young Adult
paliperidone palmitate 3-month schizophrenia relapse-free long-acting injectable paliperidone palmitate 1-month